FIELD: biotechnology.
SUBSTANCE: described is a peptide which binds with a molecule(s) of a major histocompatibility complex (MHC) selected from: (a) a peptide consisting of an amino acid sequence according to SEQ ID NO: 30, optionally elongated per 1 amino acid on its N- and/or C-terminal portion; (b) a peptide according to (a), where said peptide contains non-peptide bonds. Described also is a fused peptide, a kit and a pharmaceutical composition containing said peptide. Disclosed are nucleic acid, vector, host cell corresponding to described peptide.
EFFECT: invention expands the arsenal of cancer treatments.
20 cl, 6 dwg, 27 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIGENE PEPTIDES FOR CANCER PREVENTION AND TREATMENT | 2019 |
|
RU2812911C2 |
| VACCINE COMPOSITION FOR TREATMENT OF CANCER | 2018 |
|
RU2782261C2 |
| PEPTIDES IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR USE IN TREATING CANCER | 2020 |
|
RU2826955C2 |
| PEPTIDE OBTAINED FROM GPC3, PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER USING IT, IMMUNITY INDUCER AND METHOD FOR PRODUCING ANTIGEN-PRESENTING CELLS | 2016 |
|
RU2714117C2 |
| T-CELL COMPOSITIONS WITH T-CELL RECEPTOR DEFICIENCY | 2013 |
|
RU2781979C2 |
| NEIL3 PEPTIDES AND VACCINES COMPRISING THEM | 2010 |
|
RU2733985C2 |
| HUMAN MONOCLONAL ANTIBODIES TO THE PROTEIN OF PROGRAMMED DEATH 1 (PD-1) AND METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2016 |
|
RU2732924C2 |
| COMPOSITIONS AND METHODS FOR DIAGNOSTICS AND TREATMENT OF TUMOUR | 2010 |
|
RU2563359C2 |
| SPECIFIC ANTIBODIES TO PD-L1 AND METHODS FOR THEIR APPLICATION | 2017 |
|
RU2749109C2 |
| ANTIBODIES BINDING CTLA-4 AND APPLICATION THEREOF | 2018 |
|
RU2756100C1 |
